Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 24, Issue 10, pp. 2251-2261
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 18, 2017
- Revision received December 11, 2017
- Accepted January 12, 2018
- Published first January 17, 2018.
Article Versions
- Previous version (January 17, 2018 - 06:38).
- Previous version (April 2, 2018 - 06:29).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Kris Ann P. Schultz1,2,3,*,
- Gretchen M. Williams1,2,3,
- Junne Kamihara4,
- Douglas R. Stewart5,
- Anne K. Harris1,2,3,
- Andrew J. Bauer6,
- Joyce Turner7,
- Rachana Shah8,
- Katherine Schneider9,
- Kami Wolfe Schneider10,
- Ann Garrity Carr11,
- Laura A. Harney11,
- Shari Baldinger12,
- A. Lindsay Frazier4,
- Daniel Orbach13,
- Dominik T. Schneider14,
- David Malkin15,
- Louis P. Dehner16,
- Yoav H. Messinger1,2,3, and
- D. Ashley Hill17
- 1International Pleuropulmonary Blastoma Registry, Children's Minnesota, Minneapolis, Minnesota.
- 2Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, Minnesota.
- 3International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota.
- 4Pediatric Oncology, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Solid Tumor Programs, Boston, Massachusetts.
- 5Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
- 6Division of Endocrinology and Diabetes, Pediatric Thyroid Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
- 7Cancer Genetic Counseling Program, George Washington University, Children's National Medical Center, Washington, D.C.
- 8Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- 9Dana-Farber Cancer Institute, Center for Cancer Genetics and Prevention, Boston, Massachusetts.
- 10Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado.
- 11Westat, Rockville, Maryland.
- 12Virginia Piper Cancer Institute, Allina Health, Minneapolis, Minnesota.
- 13SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France.
- 14Clinic of Pediatrics, Municipal Hospital Dortmund, Dortmund, Germany.
- 15Division of Hematology/Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
- 16Division of Anatomic Pathology, Lauren V. Ackerman Laboratory of Surgical Pathology, Barnes-Jewish and St. Louis Children's Hospitals, Washington University Medical Center, St. Louis, Missouri.
- 17Department of Pathology, Center for Cancer and Immunology Research, Children's National Medical Center, Washington D.C.
- ↵*Corresponding Author:
Kris Ann P. Schultz, Children's Minnesota, 2525 Chicago Ave. S., Minneapolis, MN 55404. Phone: 612-813-7121; Fax: 612-813-7108; E-mail: krisann.schultz{at}childrensmn.org
May 2018
Volume 24, Issue 10
Volume 24, Issue 10
DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies
Jump to section
- Article
- Abstract
- Introduction
- Methodology
- Genotyping
- Prevalence, Inheritance, Penetrance, and Expressivity
- Indications for DICER1 Genetic Counseling and Testing
- Testing Algorithm
- Timing of Testing
- Prenatal Management
- Screening Recommendations for DICER1-associated Conditions by System
- Conclusions
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement